Electronic Total Tumor-Infiltrating Lymphocytes Predict Risk of Relapse in Patients With Melanoma

Gradient Differences of Immunotherapy Efficacy in Metastatic Melanoma Related to Sunlight Exposure Pattern: A Population-Based Study

Investigating the Role of DUSP4 in Uveal Melanoma

Phase II Clinical and Immune Correlate Study of Adjuvant Nivolumab Plus Ipilimumab for High-Risk Resected Melanoma

Deep Learning for the Detection of Anatomical Tissue Structures and Neoplasms of the Skin on Scanned Histopathological Tissue Sections

Suppressing Immune-Related Toxicity and Survival in Melanoma

Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

Prediction of Early-Stage Melanoma Recurrence Using Clinical and Histopathologic Features

Electronic Total Tumor-Infiltrating Lymphocytes Predict Risk of Relapse in Patients With Melanoma

header-info

Nov, 21, 2022

An analysis of findings from multiple studies confirmed the prognostic efficacy of tumor-infiltrating lymphocytes (TILs) in patients with melanoma and found that electronic total TILs (etTILs) outperformed automated TIL% score, calculated by the machine learning algorithm NN192.